EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. (Q47836622)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 September 2017

Language	Label	Description	Also known as
English	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial.	scientific article published on 8 September 2017

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

author name string

Michaela Angelika Ihle

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Dido Lenze

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Annika Lehmann

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Michael Hummel

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Claudia Vollbrecht

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Roland Penzel

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Albrecht Stenzinger

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Volker Endris

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Andreas Jung

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Ulrich Lehmann

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Silke Zeugner

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Gustavo Baretton

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Hans Kreipe

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Peter Schirmacher

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Thomas Kirchner

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Reinhard Büttner

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Sabine Merkelbach-Bruse

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Manfred Dietel

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

publication date

8 September 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Virchows Archiv

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

471

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

509-520

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

https://scigraph.springernature.com/pub.10.1007/s00428-017-2226-8

0 references

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

EGFR mutations in lung cancer: from tissue testing to liquid biopsy

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Impact of the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology clinical practice guidelines for EGFR and ALK testing in lung cancer in Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnostics

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Pharmacotherapy targeting the EGFR oncogene in NSCLC.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Circulating nucleic acids in plasma/serum

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society.

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies

1 reference

https://api.crossref.org/works/10.1007%2FS00428-017-2226-8

21 January 2018

Identifiers

10.1007/S00428-017-2226-8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28884371%20AND%20SRC:MED&resulttype=core&format=json

29 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47836622&oldid=1282437827"